Everolimus in metastatic renal cell carcinoma: Preliminary experience from chang gung memorial hospital

Wen Kuan Huan; Chuang Chi Liaw; See Tong Pang; Cheng Keng Chuang; Yang Jen Chiang; Chun Te Wu; Ying Hsu Chang; Hung Ming Wang; Yung Chang Lin; Jia Juan Hsieh; Li Ying Ou; Shih I. Tsai; Chih Hsun Yang; Cheng Ta Yang; John Wen Cheng Chang

Everolimus in metastatic renal cell carcinoma: Preliminary experience from chang gung memorial hospital

Wen Kuan Huan, Chuang Chi Liaw, See Tong Pang, Cheng Keng Chuang, Yang Jen Chiang, Chun Te Wu, Ying Hsu Chang, Hung Ming Wang, Yung Chang Lin, Jia Juan Hsieh, Li Ying Ou, Shih I. Tsai, Chih Hsun Yang, Cheng Ta Yang, John Wen Cheng Chang

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: Everolimus has been approved for second-line treatment of patients with metstatic renal cell carcinoma (mRCC) after failure of sorafenib or suni-tinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinas inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method. Results Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematological adverse events with everolimus were mucositis, rash, epis-taxis and pneumonitis. Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC The toxicity is tolerable and manageable.

Original language	English
Pages (from-to)	402-407
Number of pages	6
Journal	Chang Gung Medical Journal
Volume	35
Issue number	5
Publication status	Published - 2012
Externally published	Yes

Keywords

Everolimus
Mammalian target of rapamycin (mTOR) inhibitor
Renal cell cancer

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4a94370318e54de2ad922ef4f5454c4d,

title = "Everolimus in metastatic renal cell carcinoma: Preliminary experience from chang gung memorial hospital",

abstract = "Background: Everolimus has been approved for second-line treatment of patients with metstatic renal cell carcinoma (mRCC) after failure of sorafenib or suni-tinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinas inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method. Results Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematological adverse events with everolimus were mucositis, rash, epis-taxis and pneumonitis. Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC The toxicity is tolerable and manageable.",

keywords = "Everolimus, Mammalian target of rapamycin (mTOR) inhibitor, Renal cell cancer",

author = "Huan, {Wen Kuan} and Liaw, {Chuang Chi} and Pang, {See Tong} and Chuang, {Cheng Keng} and Chiang, {Yang Jen} and Wu, {Chun Te} and Chang, {Ying Hsu} and Wang, {Hung Ming} and Lin, {Yung Chang} and Hsieh, {Jia Juan} and Ou, {Li Ying} and Tsai, {Shih I.} and Yang, {Chih Hsun} and Yang, {Cheng Ta} and Chang, {John Wen Cheng}",

year = "2012",

language = "English",

volume = "35",

pages = "402--407",

journal = "Chang Gung Medical Journal",

issn = "2072-0939",

publisher = "Chang Gung Medical Journal",

number = "5",

}

TY - JOUR

T1 - Everolimus in metastatic renal cell carcinoma

T2 - Preliminary experience from chang gung memorial hospital

AU - Huan, Wen Kuan

AU - Liaw, Chuang Chi

AU - Pang, See Tong

AU - Chuang, Cheng Keng

AU - Chiang, Yang Jen

AU - Wu, Chun Te

AU - Chang, Ying Hsu

AU - Wang, Hung Ming

AU - Lin, Yung Chang

AU - Hsieh, Jia Juan

AU - Ou, Li Ying

AU - Tsai, Shih I.

AU - Yang, Chih Hsun

AU - Yang, Cheng Ta

AU - Chang, John Wen Cheng

PY - 2012

Y1 - 2012

N2 - Background: Everolimus has been approved for second-line treatment of patients with metstatic renal cell carcinoma (mRCC) after failure of sorafenib or suni-tinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinas inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method. Results Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematological adverse events with everolimus were mucositis, rash, epis-taxis and pneumonitis. Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC The toxicity is tolerable and manageable.

AB - Background: Everolimus has been approved for second-line treatment of patients with metstatic renal cell carcinoma (mRCC) after failure of sorafenib or suni-tinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinas inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method. Results Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematological adverse events with everolimus were mucositis, rash, epis-taxis and pneumonitis. Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC The toxicity is tolerable and manageable.

KW - Everolimus

KW - Mammalian target of rapamycin (mTOR) inhibitor

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=84869065860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869065860&partnerID=8YFLogxK

M3 - Article

C2 - 23127345

AN - SCOPUS:84869065860

SN - 2072-0939

VL - 35

SP - 402

EP - 407

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

IS - 5

ER -

Everolimus in metastatic renal cell carcinoma: Preliminary experience from chang gung memorial hospital

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this